NYSE:LLY - Eli Lilly And Co Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$118.20 +1.62 (+1.39 %)
(As of 05/22/2019 03:09 PM ET)
Previous Close$116.58
Today's Range$116.03 - $118.22
52-Week Range$81.61 - $132.13
Volume117,593 shs
Average Volume12.64 million shs
Market Capitalization$114.75 billion
P/E Ratio21.29
Dividend Yield2.22%
Beta0.27
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of rheumatoid arthritis and plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; AC Immune SA; and Avidity Biosciences, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP53245710
Phone317-276-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.56 billion
Cash Flow$7.0736 per share
Book Value$2.64 per share

Profitability

Net Income$3.23 billion

Miscellaneous

Employees33,610
Market Cap$114.75 billion
Next Earnings Date7/23/2019 (Estimated)
OptionableOptionable

Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co announced a quarterly dividend on Monday, May 6th. Shareholders of record on Friday, May 17th will be given a dividend of $0.645 per share on Monday, June 10th. This represents a $2.58 annualized dividend and a yield of 2.18%. The ex-dividend date is Thursday, May 16th. View Eli Lilly And Co's Dividend History.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) posted its quarterly earnings results on Tuesday, April, 30th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS. View Eli Lilly And Co's Earnings History.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July 23rd 2019. View Earnings Estimates for Eli Lilly And Co.

How can I listen to Eli Lilly And Co's earnings call?

Eli Lilly And Co will be holding an earnings conference call on Tuesday, July 30th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co issued an update on its FY19 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of $5.60-5.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.61. The company issued revenue guidance of $22-22.5 billion, compared to the consensus revenue estimate of $22.22 billion.Eli Lilly And Co also updated its FY 2019 guidance to $5.60-5.70 EPS.

What price target have analysts set for LLY?

20 brokerages have issued 12-month price objectives for Eli Lilly And Co's stock. Their forecasts range from $74.51 to $143.00. On average, they anticipate Eli Lilly And Co's share price to reach $117.5467 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for Eli Lilly And Co.

What is the consensus analysts' recommendation for Eli Lilly And Co?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 10 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.

What are Wall Street analysts saying about Eli Lilly And Co stock?

Here are some recent quotes from research analysts about Eli Lilly And Co stock:
  • 1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter.  However, Lilly lowered its sales guidance for 2019.  Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)

Has Eli Lilly And Co been receiving favorable news coverage?

Media coverage about LLY stock has been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eli Lilly And Co earned a daily sentiment score of 0.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Are investors shorting Eli Lilly And Co?

Eli Lilly And Co saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 16,664,689 shares, a decrease of 38.2% from the April 15th total of 26,966,991 shares. Based on an average daily trading volume, of 6,733,069 shares, the short-interest ratio is presently 2.5 days. Currently, 1.8% of the company's stock are sold short. View Eli Lilly And Co's Current Options Chain.

Who are some of Eli Lilly And Co's key competitors?

What other stocks do shareholders of Eli Lilly And Co own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Intel (INTC), General Electric (GE), Bank of America (BAC), Bristol-Myers Squibb (BMY), Verizon Communications (VZ), AT&T (T) and Gilead Sciences (GILD).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
  • Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
  • Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.28%), BlackRock Inc. (6.29%), Primecap Management Co. CA (4.45%), Wellington Management Group LLP (3.78%), FMR LLC (1.43%) and Geode Capital Management LLC (1.26%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

Which major investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Primecap Management Co. CA, Amundi Pioneer Asset Management Inc., Lilly Endowment Inc., AJO LP, Geode Capital Management LLC and AQR Capital Management LLC. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.

Which major investors are buying Eli Lilly And Co stock?

LLY stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Renaissance Technologies LLC, Morgan Stanley, Goelzer Investment Management Inc., California Public Employees Retirement System, FMR LLC, Jennison Associates LLC and Handelsbanken Fonder AB. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky and Jackson P Tai. View Insider Buying and Selling for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $118.21.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $114.76 billion and generates $24.56 billion in revenue each year. The company earns $3.23 billion in net income (profit) each year or $5.55 on an earnings per share basis. Eli Lilly And Co employs 33,610 workers across the globe.

What is Eli Lilly And Co's official website?

The official website for Eli Lilly And Co is http://www.lilly.com/.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  960 (Thanks for Voting!)
Underperform Votes:  763 (Thanks for Voting!)
Total Votes:  1,723
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Featured Article: Call Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel